Tadalafil

PEPTIDES+ MEMBERS ONLY

INDICATIONS FOR USE

Tadalafil is FDA-approved for the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). It is also used off-label to manage conditions such as Raynaud’s phenomenon and endothelial dysfunction.

ROUTE OF ADMINISTRATION

  • Administered orally in tablet or troche form.

FORMULATIONS AND PRICING

FormulationPrice
20mg troche (#15/#30)$47 / $75
40mg troche (#15/#30)$47 / $75

COMMON INITIAL DOSING REGIMENS

  • For Erectile Dysfunction: An initial dose of 10 mg taken orally before anticipated sexual activity is common, with a maximum frequency of once per day. For daily use, a lower dose of 2.5–5 mg is recommended, irrespective of timing of sexual activity.

MECHANISM OF ACTION

  • Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. By inhibiting PDE5, tadalafil prevents the breakdown of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum, pulmonary vasculature, and other vascular tissues.

  • In ED, increased cGMP levels result in enhanced smooth muscle relaxation and increased blood flow to the penis during sexual stimulation, promoting erection.

  • Tadalafil is distinguished by its long half-life (17.5 hours), which provides a prolonged duration of action, often referred to as the “weekend pill.”

COMMON SIDE EFFECTS

  • Cardiovascular: Headache, flushing, and dizziness are common due to systemic vasodilation. Hypotension and tachycardia may occur but are less common.

  • Gastrointestinal: Dyspepsia, nausea, and abdominal pain.

  • Musculoskeletal: Back pain and myalgia are unique side effects of tadalafil, possibly related to PDE11 inhibition.

  • Respiratory: Nasal congestion.

  • Rare but Severe: Non-arteritic anterior ischemic optic neuropathy (NAION), sudden hearing loss, and priapism (prolonged erection requiring medical attention).

CONTRAINDICATIONS

  • Absolute: Hypersensitivity to finasteride or any excipient in the formulation. Pregnant or potentially pregnant women should not handle finasteride-containing products due to the risk of absorption and potential harm to a male fetus.

  • Relative: Patients with significant scalp irritation or broken skin should use topical finasteride cautiously to avoid increased systemic absorption. Use in women for androgenetic alopecia remains off-label and requires careful consideration.

ADDITIONAL NOTES ON EFFICACY

  • Absolute: Concurrent use with nitrates (e.g., nitroglycerin) or guanylate cyclase stimulators (e.g., riociguat) due to the risk of severe hypotension. Hypersensitivity to tadalafil or any excipient.

  • Relative: Use cautiously in individuals with severe hepatic or renal impairment, severe cardiovascular conditions, significant hypotension (<90/50 mmHg), or a recent history of stroke or myocardial infarction. Patients with retinitis pigmentosa or predisposing conditions for priapism (e.g., sickle cell anemia, multiple myeloma, leukemia) require additional caution.

COMPARISON WITH SILDENAFIL

  • Tadalafil has a longer half-life (17.5 hours) compared to sildenafil (4–6 hours), allowing for greater flexibility with dosing and a prolonged therapeutic window. This makes tadalafil suitable for daily dosing and sustained effects (“weekend pill”).

  • Tadalafil also has unique efficacy in managing BPH, which sildenafil does not address. Both medications share similar side effects, but tadalafil has a distinct risk of musculoskeletal pain.

MORE INFORMATION

  • FDA Safety Data Sheet for tadalafil may be found here.

  • Gong B. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017 [PubMed Link]

  • Prasetyo DT. Tadalafil Once a Day for Men with Erectile Dysfunction: Is It Superior than On-Demand Administration?. Acta Med Indones. 2019 [PubMed Link]

  • Mykoniatis I. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 [PubMed Link]

  • Frajese GV. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clin Interv Aging. 2006 [PubMed Link]

  • Bansal UK. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology. 2018 [PubMed Link]

  • Wang Y. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms. 2018 [PubMed Link]

  • Yıldırım Ç. Comparison of three different tadalafil regimens for erectile dysfunction treatment in patients with diabetes mellitus microvascular complications. Andrologia. 2022 [PubMed Link]

  • Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. Int J Impot Res. 2007 [PubMed Link]